Clinical Trials
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Johnson & Johnson announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by...
Clinical Trials
I-Mab receives China NMPA clearance to begin phase 1 trial of lemzoparlimab in relapsed/refractory advanced lymphoma
I-Mab, a clinical stage biopharmaceutical company, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared...
News
US FDA grants fast track status to Gyroscope’s GT005 to treat dry age-related macular degeneration
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the US FDA has granted Fast Track designation to GT005 for the treatment...
News
AstraZeneca’s Lynparza recommended by the EMA for HRD-positive advanced ovarian cancer
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment with bevacizumab for patients...
Press Releases
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19...
News
Bristol Myers Squibb Completes Acquisition of Forbius
Bristol Myers Squibb announced that it has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200,...
Press Releases
Sun Pharma Announces the Launch of ILUMYA for Treatment of Plaque Psoriasis in Japan
Sun Pharmaceutical Industries Limited and includesits subsidiaries and/or associate companies) announced that its wholly-owned Japanese subsidiary has launched ILUMYA® Subcutaneous Injection 100 mg Syringe...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read